These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 3130780)

  • 1. Comparison of meningococcal outer membrane protein vaccines solubilized with detergent or C polysaccharide.
    Poolman JT; Timmermans HA; Hopman CT; Teerlink T; Van Vught PA; Witvliet MH; Beuvery EC
    Antonie Van Leeuwenhoek; 1987; 53(6):413-9. PubMed ID: 3130780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional activities and epitope specificity of human and murine antibodies against the class 4 outer membrane protein (Rmp) of Neisseria meningitidis.
    Rosenqvist E; Musacchio A; Aase A; Høiby EA; Namork E; Kolberg J; Wedege E; Delvig A; Dalseg R; Michaelsen TE; Tommassen J
    Infect Immun; 1999 Mar; 67(3):1267-76. PubMed ID: 10024570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Specificity of human bactericidal antibodies against PorA P1.7,16 induced with a hexavalent meningococcal outer membrane vesicle vaccine.
    van der Voort ER; van der Ley P; van der Biezen J; George S; Tunnela O; van Dijken H; Kuipers B; Poolman J
    Infect Immun; 1996 Jul; 64(7):2745-51. PubMed ID: 8698504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody responses to serogroup B meningococcal outer membrane antigens after vaccination and infection.
    Rosenqvist E; Harthug S; Frøholm LO; Høiby EA; Bøvre K; Zollinger WD
    J Clin Microbiol; 1988 Aug; 26(8):1543-8. PubMed ID: 3139705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neisseria meningitidis serogroup C polysaccharide and serogroup B outer membrane vesicle conjugate as a bivalent meningococcus vaccine candidate.
    Fukasawa LO; Gorla MC; Schenkman RP; Garcia LR; Carneiro SM; Raw I; Tanizaki MM
    Vaccine; 1999 Aug; 17(23-24):2951-8. PubMed ID: 10462229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protection against group B Neisseria meningitidis disease: preparation of soluble protein and protein-polysaccharide immunogens.
    Frasch CE; Peppler MS
    Infect Immun; 1982 Jul; 37(1):271-80. PubMed ID: 6809629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Meningococcal lipopolysaccharide (LPS)-derived oligosaccharide-protein conjugates evoke outer membrane protein- but not LPS-specific bactericidal antibodies in mice: influence of adjuvants.
    Verheul AF; Van Gaans JA; Wiertz EJ; Snippe H; Verhoef J; Poolman JT
    Infect Immun; 1993 Jan; 61(1):187-96. PubMed ID: 8418041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Class 1/3 outer membrane protein vaccine against group B, type 15, subtype 16 meningococci.
    Poolman JT; Beuvery EC; Hopman CT; Witvliet MH; Timmermans HA; Teerlink T; Zanen HC
    Dev Biol Stand; 1986; 63():147-52. PubMed ID: 3091433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody studies in mice of outer membrane antigens for use in an improved meningococcal B and C vaccine.
    Milagres LG; Cristina M; Brandileone MC; Sacchi CT; Vieira VS; Zanella RC; Frasch CE
    FEMS Immunol Med Microbiol; 1996 Jan; 13(1):9-17. PubMed ID: 8821393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunization with meningococcal class 1 outer membrane protein produced in Bacillus subtilis and reconstituted in the presence of Zwittergent or Triton X-100.
    Idänpään-Heikkilä I; Wahlström E; Muttilainen S; Nurminen M; Käyhty H; Sarvas M; Mäkelä PH
    Vaccine; 1996 Jun; 14(9):886-91. PubMed ID: 8843630
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody response of adults to an aluminum hydroxide-adsorbed Neisseria meningitidis serotype 2b protein-group B polysaccharide vaccine.
    Frasch CE; Zahradnik JM; Wang LY; Mocca LF; Tsai CM
    J Infect Dis; 1988 Oct; 158(4):710-8. PubMed ID: 3139776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity and safety of a hexavalent meningococcal outer-membrane-vesicle vaccine in children of 2-3 and 7-8 years of age.
    de Kleijn ED; de Groot R; Labadie J; Lafeber AB; van den Dobbelsteen G; van Alphen L; van Dijken H; Kuipers B; van Omme GW; Wala M; Juttmann R; Rümke HC
    Vaccine; 2000 Feb; 18(15):1456-66. PubMed ID: 10618543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monoclonal antibodies against the 70-kilodalton iron-regulated protein of Neisseria meningitidis are bactericidal and strain specific.
    Pettersson A; Kuipers B; Pelzer M; Verhagen E; Tiesjema RH; Tommassen J; Poolman JT
    Infect Immun; 1990 Sep; 58(9):3036-41. PubMed ID: 1696939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile.
    Tappero JW; Lagos R; Ballesteros AM; Plikaytis B; Williams D; Dykes J; Gheesling LL; Carlone GM; Høiby EA; Holst J; Nøkleby H; Rosenqvist E; Sierra G; Campa C; Sotolongo F; Vega J; Garcia J; Herrera P; Poolman JT; Perkins BA
    JAMA; 1999 Apr; 281(16):1520-7. PubMed ID: 10227322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Production, characterization and control of a Neisseria meningitidis hexavalent class 1 outer membrane protein containing vesicle vaccine.
    Claassen I; Meylis J; van der Ley P; Peeters C; Brons H; Robert J; Borsboom D; van der Ark A; van Straaten I; Roholl P; Kuipers B; Poolman J
    Vaccine; 1996 Jul; 14(10):1001-8. PubMed ID: 8873395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of aluminium hydroxide and meningococcal serogroup C capsular polysaccharide on the immunogenicity and reactogenicity of a group B Neisseria meningitidis outer membrane vesicle vaccine.
    Rosenqvist E; Høiby EA; Bjune G; Aase A; Halstensen A; Lehmann AK; Paulssen J; Holst J; Michaelsen TE; Nøkleby H; Frøholm LO; Closs O
    Dev Biol Stand; 1998; 92():323-33. PubMed ID: 9554288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human bactericidal antibody response to meningococcal outer membrane protein vaccines.
    Zollinger WD; Boslego J; Frøholm LO; Ray JS; Moran EE; Brandt BL
    Antonie Van Leeuwenhoek; 1987; 53(6):403-11. PubMed ID: 3130779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A linear B-cell epitope on the class 3 outer-membrane protein of Neisseria meningitidis recognized after vaccination with the Norwegian group B outer-membrane vesicle vaccine.
    Delvig AA; Wedege E; Caugant DA; Dalseg R; Kolberg J; Achtman M; Rosenqvist E
    Microbiology (Reading); 1995 Jul; 141 ( Pt 7)():1593-600. PubMed ID: 7551027
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A native outer membrane vesicle vaccine confers protection against meningococcal colonization in human CEACAM1 transgenic mice.
    Pajon R; Buckwalter CM; Johswich KO; Gray-Owen SD; Granoff DM
    Vaccine; 2015 Mar; 33(11):1317-1323. PubMed ID: 25662856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The capsular polysaccharide of group B Neisseria meningitidis as a vehicle for vaccine development.
    Jennings HJ
    Contrib Microbiol Immunol; 1989; 10():151-65. PubMed ID: 2479499
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.